TVGN vs. TARA, INKT, ACHL, PLUR, CRTX, INAB, NKGN, CYTH, AIM, and EVAX
Should you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Protara Therapeutics (TARA), MiNK Therapeutics (INKT), Achilles Therapeutics (ACHL), Pluri (PLUR), Cortexyme (CRTX), IN8bio (INAB), NKGen Biotech (NKGN), Cyclo Therapeutics (CYTH), AIM ImmunoTech (AIM), and Evaxion Biotech A/S (EVAX). These companies are all part of the "medical" sector.
Protara Therapeutics (NASDAQ:TARA) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends.
Protara Therapeutics' return on equity of -21.83% beat Tevogen Bio's return on equity.
Protara Therapeutics received 30 more outperform votes than Tevogen Bio when rated by MarketBeat users.
Protara Therapeutics has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500.
Protara Therapeutics currently has a consensus target price of $26.50, indicating a potential upside of 807.53%. Given Tevogen Bio's higher possible upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Tevogen Bio.
38.1% of Protara Therapeutics shares are held by institutional investors. 18.4% of Protara Therapeutics shares are held by company insiders. Comparatively, 56.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Tevogen Bio had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for Tevogen Bio and 3 mentions for Protara Therapeutics. Tevogen Bio's average media sentiment score of 0.00 beat Protara Therapeutics' score of -0.25 indicating that Protara Therapeutics is being referred to more favorably in the media.
Summary
Protara Therapeutics beats Tevogen Bio on 6 of the 11 factors compared between the two stocks.
Get Tevogen Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tevogen Bio Competitors List
Related Companies and Tools
